Alphatec Holdings Inc. (NASDAQ:ATEC) is one of the best high short interest stocks with biggest upside potential. On January 27, TD Cowen lowered its price target for Alphatec to $20 from $27 while maintaining a Buy rating following a transfer of coverage. The firm suggested that the current market expectations do not fully appreciate the company’s growth vectors, such as its recent 2026 revenue outlook of $890 million and the acquisition of exclusive US rights to Theradaptive’s OsteoAdapt bone graft. The ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Viewpoint - Alphatec (ATEC) shares experienced a significant increase of 9.5% to close at $17.46, driven by strong trading volume and investor optimism regarding its preliminary financial results for 2025 and strategic acquisitions [1][2]. Financial Performance - For 2026, Alphatec projects total revenue of $890 million, indicating a growth of approximately 17% compared to the full year 2025 [2]. - The company is expected to report quarterly earnings of $0.04 per share, reflecting a year-over-year increase of 117.4% [3]. - Revenues for the upcoming quarter are anticipated to be $212.6 million, which is a 20.3% increase from the same quarter last year [3]. Market Position and Trends - The consensus EPS estimate for Alphatec has remained unchanged over the last 30 days, suggesting stability in earnings expectations [4]. - The stock currently holds a Zacks Rank of 3 (Hold), indicating a neutral outlook [4]. - In the same medical instruments industry, Integer (ITGR) has also maintained a Zacks Rank of 3, with an EPS estimate of $1.7, representing an 18.9% increase from the previous year [5].

Core Insights - Alphatec Holdings, Inc. (NASDAQ:ATEC) is recognized as one of the top 14 booming stocks to consider for investment at present [1] Financial Performance - Preliminary total revenue for 2025 increased by 25%, expected to be between $763.4 million and $764.4 million, primarily driven by a 26% surge in surgical revenue [2] - The company reaffirmed its full-year guidance for adjusted EBITDA at $91 million and ended the year with a cash balance of $161 million [2] 2026 Outlook - For fiscal 2026, Alphatec projects revenue of $890 million, with 90% expected to be surgical-related [3] - Adjusted EBITDA is anticipated to be around $130 million, and free cash flow for the year is forecasted at approximately $20 million [3] Strategic Developments - On the same day, Alphatec announced a strategic agreement with Theradaptive, Inc. to acquire exclusive distribution rights in the U.S. for Theradaptive's rhBMP-2 solution, OsteoAdapt, enhancing its position in the procedural ecosystem [4] Market Sentiment - Wall Street has a bullish outlook on Alphatec, with a consensus Strong Buy rating and a one-year average share price target of $24.55, indicating an upside of nearly 40% as of January 12 [5]

This article looks at the 14 Best Booming Stocks to Buy Right Now.The S&P 500 registered gains of 16% in 2025, marking the third successive year of double-digit returns after the broad market index rallied 24% in 2023 and then 23% in 2024.Total gains over the past three years have amounted to approximately 80%, the strongest run over a three-year win streak since the index surged 90% between 2019 and 2021.A Financial Times survey of major investment banks in December forecast a 10% gain in the S&P 500 in 20 ...

Serves spine surgeons and healthcare providers specializing in the surgical treatment of spinal pathologies, with a focus on the U.S. market.Generates revenue primarily through the sale of proprietary medical devices and related products to hospitals and surgical centers, distributed via a direct sales force and independent distributors in the U.S.Does the reduced size reflect a change in selling cadence or remaining capacity? The declining trade size is consistent with reduced remaining share capacity, as ...

Core Viewpoint - Alphatec Spine is focused on delivering long-term differentiated growth in the spine industry, highlighting a strong track record of execution and significant growth opportunities within the sector [1][2]. Group 1: Company Performance - The management team emphasizes a consistent track record of execution over the past eight years, indicating stability and reliability in the company's operations [2][3]. - The company believes it is an opportune time to be involved in the spine market, suggesting favorable market conditions for growth [3]. Group 2: Growth Opportunities - There are substantial growth opportunities within the medical supplies and devices space, particularly in spine-related products and services [2]. - The company is building a strong infrastructure to support its growth initiatives, which is expected to enhance its market position [2].

Summary of Alphatec Conference Call Company Overview - **Company**: Alphatec Spine - **Industry**: Medical Supplies and Devices, specifically focused on spinal surgery Key Points and Arguments Growth and Financial Performance - Alphatec aims for long-term differentiated growth, with a strong track record of execution and significant growth opportunities in the spine market [2][3] - The company finished 2025 with $764 million in revenue, reflecting a 25% growth, and expects to reach $890 million in revenue by 2026, representing a 17% growth [4][6] - Adjusted EBITDA for 2025 was projected at $91 million (12% of revenue), with expectations of $130 million (15% margin) by 2026 [4][6] - The company has committed to becoming a $1 billion revenue company by 2027, with $180 million in Adjusted EBITDA [5] Market Position and Strategy - Alphatec is now the third largest U.S. market share holder in the spine market, with less than 10% market share across the top 10 U.S. markets, indicating significant growth potential [5][24] - The company has focused on creating clinical distinction to compel surgeon adoption, achieving over 20% growth in surgeon adoption this year [7][8] - The strategy includes proceduralization, which emphasizes the assembly of goods for spine surgery rather than selling individual parts [3][11] Innovations and Technology - Alphatec has made significant investments in informatics and procedural tools, including the acquisition of EOS, a full-body imaging system, and the development of SafeOp, a neurophysiology tool [19][13] - The company is focused on integrating informatics into surgical workflows to improve decision-making and outcomes, with plans to launch Valence, a navigation and robotic tool, in 2026 [14][15][19] - The informatics play is seen as a key driver of long-term value, with a focus on capturing data to enhance surgical decision-making [24][20] Market Dynamics and Competition - The company views recent disruptions in the spine market, such as spin-offs from larger med tech companies, as potential tailwinds for growth [40][41] - Alphatec believes its commitment to neurophysiology and sophisticated surgical tools provides a competitive advantage over fast-following competitors [44][46] Future Outlook - The company anticipates continued strong growth driven by surgical volume and adoption, with a target of $100 million in EOS revenue by 2027 [32][25] - Seasonality effects are expected to influence revenue patterns, particularly with the growing presence in pediatric deformity [31][35] - Alphatec is focused on maintaining profitability while investing in R&D and sales channels to support growth [50][51] Conclusion - The financial outlook for Alphatec is positive, with a commitment to achieving $890 million in revenue and $130 million in Adjusted EBITDA by 2026, alongside a focus on innovation and market expansion [29][50]

If you like to see more ideas, please subscribe to the premium service "Value in Corporate Events" here and try the free trial. In this service we cover major earnings events, M&A, IPOs and other significant corporate events with actionable ideas. Furthermore, we provide coverage of situations and names on request!Over the summer, I concluded that Alphatec Holdings, Inc. ( ATEC ) was delivering on continued growth while narrowing losses. While this was to be applauded, I feared persistent losses and continu ...

ATEC Secures Exclusive U.S. Rights to OsteoAdapt® Platform in Major Strategic Alignment Theradaptive Initiates Series B to Advance Proprietary Protein-Engineering Technology CARLSBAD, Calif. and FREDERICK, Md., Jan. 12, 2026 /PRNewswire/ -- Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing spine surgery, and Theradaptive, Inc., a clinical-stage regenerative medicine company pioneering engineered protein therapeutics, today announced a definitive strategi ...